Evidence map›Paper›PMID 22299628›Full record

ArticleJournal of the American Chemical Society2012

The mechanism of substrate inhibition in human indoleamine 2,3-dioxygenase.

Igor Efimov, Jaswir Basran, Xiao Sun, Nishma Chauhan, Stephen K Chapman, Christopher G Mowat, Emma Lloyd Raven

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Species Differences in Tryptophan Metabolism and Disposition.International journal of tryptophan research : IJTR · 2022
    Review
  11. Review
  12. Conformational Plasticity in Human Heme-Based Dioxygenases.Journal of the American Chemical Society · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Inhibition Mechanisms of Human Indoleamine 2,3 Dioxygenase 1.Journal of the American Chemical Society · 2018
    Article
  18. Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Igor EfimovDepartment of Chemistry, University of Leicester, University Road, Leicester LE1 7RH, United Kingdom.
Jaswir Basran
Xiao Sun
Nishma Chauhan
Stephen K Chapman
Christopher G Mowat
Emma Lloyd Raven
University of Leicester · GBHeriot-Watt University · GBUniversity of Edinburgh · GB

Funding

Wellcome TrustWellcome Trust 083636
6 · The paper itself

Abstract

Indoleamine 2,3-dioxygenase catalyzes the O(2)-dependent oxidation of L-tryptophan (L-Trp) to N-formylkynurenine (NFK) as part of the kynurenine pathway. Inhibition of enzyme activity at high L-Trp concentrations was first noted more than 30 years ago, but the mechanism of inhibition has not been established. Using a combination of kinetic and reduction potential measurements, we present evidence showing that inhibition of enzyme activity in human indoleamine 2,3-dioxygenase (hIDO) and a number of site-directed variants during turnover with L-tryptophan (L-Trp) can be accounted for by the sequential, ordered binding of O(2) and L-Trp. Analysis of the data shows that at low concentrations of L-Trp, O(2) binds first followed by the binding of L-Trp; at higher concentrations of L-Trp, the order of binding is reversed. In addition, we show that the heme reduction potential (E(m)(0)) has a regulatory role in controlling the overall rate of catalysis (and hence the extent of inhibition) because there is a quantifiable correlation between E(m)(0) (that increases in the presence of L-Trp) and the rate constant for O(2) binding. This means that the initial formation of ferric superoxide (Fe(3+)-O(2)(•-)) from Fe(2+)-O(2) becomes thermodynamically less favorable as substrate binds, and we propose that it is the slowing down of this oxidation step at higher concentrations of substrate that is the origin of the inhibition. In contrast, we show that regeneration of the ferrous enzyme (and formation of NFK) in the final step of the mechanism, which formally requires reduction of the heme, is facilitated by the higher reduction potential in the substrate-bound enzyme and the two constants (k(cat) and E(m)(0)) are shown also to be correlated. Thus, the overall catalytic activity is balanced between the equal and opposite dependencies of the initial and final steps of the mechanism on the heme reduction potential. This tuning of the reduction potential provides a simple mechanism for regulation of the reactivity, which may be used more widely across this family of enzymes.

Indexed as

BiochemistryCatalysisChemistry, PharmaceuticalHemeHumansIndoleamine-Pyrrole 2,3,-DioxygenaseKineticsKynurenineMutagenesis, Site-DirectedOxygenProtein BindingSubstrate SpecificityThermodynamicsTryptophanHemeIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenineN'-formylkynurenineOxygenTryptophan

Identifiers

PMID22299628
PMCPMC3280726
OpenAlexW2141625866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.